ArticleBMC cancer2025
Global and regional burden of kidney cancer from 1990 to 2021: analysis and future predictions based on global burden of disease study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Prognosis Comparison Between Synchronous and Metachronous Metastasis of Renal Cell Carcinoma: A Meta-Analysis and Systematic Review.Annals of surgical oncology · 2026Review
- Burden and Trends of Genitourinary Cancers Across the Americas: A GBD 2023 Analysis of Regional Socioeconomic Gradients.Cancers · 2026Article
- Epidemiological Trends and Burden of Adult Kidney Cancer in Saudi Arabia: A 42-Year Retrospective Analysis (1982-2023).Cancer reports (Hoboken, N.J.) · 2026Observational
- Network toxicology and single-cell transcriptomics nominate candidate pyrethroid-associated targets and pathways in clear cell renal cell carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis.World journal of urology · 2026Article
- Kidney Tumor Segmentation With a Multistage Adaptive Boundary-Aware Network.Annals of the New York Academy of Sciences · 2026Article
- Emerging role of low-frequency somatic mutations in cancer relapse: from early detection to precision oncology.Frontiers in oncology · 2026Review
- Integrated analysis uncoversInternational journal of medical sciences · 2026Article
- Global and regional burden of kidney cancer from 1990 to 2021: analysis and future predictions based on global burden of disease study.BMC cancer · 2025Article
- Article
- Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence and mortality of kidney cancer vary widely globally. This study aims to examine the global burden and trends of kidney cancer from 1990 to 2021 and its associations with various factors.
methodsData on kidney cancer cases and age-standardized rates (ASRs) of incidence, prevalence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021 were collected and analyzed globally. The age-period-cohort (APC) and Bayesian age-period-cohort (BAPC) models were used to track disease burden dynamics and predict future trends.
resultsGlobally, the incidence of kidney cancer increased from 1.6 × 105 in 1990 to 3.9 × 105 in 2021. China had the most cases, deaths and DALYs in 2021, followed by the United States. Cabo Verde had the fastest growth in ASRs, whereas Southern Latin America had the highest ASRs. Forty-nine countries or regions, mainly in Western Europe and North America, had a decreasing trend in ASR for mortality over the period. Overall, the burden of kidney cancer increased with a higher sociodemographic index (SDI). The APC and BAPC models predicted a steady decline in the ASRs for incidence, prevalence, mortality and DALYs for kidney cancer over the next 20 years. High body mass index (BMI) and smoking were major risk factors, with high BMI being prominent in low-SDI countries.
conclusionsFrom 1990 to 2021, the global burden of kidney cancer represented a significant health threat. Policies to reduce exposure to risk factors could be beneficial amid global aging trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.